Holen Sie sich die Stockscreener-App
1.40
3.70%
0.05
Handel nachbörslich:
1.51
0.11
+7.86%
Schlusskurs vom Vortag:
$1.35
Offen:
$1.35
24-Stunden-Volumen:
24,124
Relative Volume:
0.01
Marktkapitalisierung:
$4.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.71M
KGV:
-3.1963
EPS:
-0.438
Netto-Cashflow:
$-8.81M
1W Leistung:
-7.89%
1M Leistung:
-9.09%
6M Leistung:
-47.70%
1J Leistung:
+299.89%
1-Tages-Spanne:
$1.35
$1.65
1-Wochen-Bereich:
$1.29
$1.65
52-Wochen-Spanne:
$0.2635
$7.00
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Firmenname
Xortx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
XORTX Highlights Kidney Disease Study at ASN - TipRanks
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - GlobeNewswire
XORTX Secures $1.5 Million in Latest Offering - TipRanks
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN
XORTX Therapeutics Announces $1.5 Million Offering - TipRanks
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
The Significance of Moving Averages in XORTX Therapeutics Inc Inc. (XRTX) Price Performance - The InvestChronicle
XORTX Therapeutics Advances Precision Kidney Care - TipRanks
XORTX Initiates Precision Medicine Program - GlobeNewswire
XORTX Therapeutics Inc. Initiates Precision Medicine Program - Marketscreener.com
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
XORTX Therapeutics (NASDAQ:XRTX) Stock Quotes, Forecast and News Summary - Benzinga
SEC Form 424B3 filed by XORTX Therapeutics Inc. - Quantisnow
Form 424B3 XORTX Therapeutics Inc. - StreetInsider.com
XORTX Therapeutics Shareholders Approve Key Decisions - TipRanks
XORTX Announces Results of Annual and Special Meeting of Shareholders - GlobeNewswire
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - GlobeNewswire
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Ford Motor Company (F-N) QuotePress Release - The Globe and Mail
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
XORTX Prepares for Shareholders’ Vote on Key Resolutions - TipRanks
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders - GlobeNewswire
In the Green: XORTX Therapeutics Inc (XRTX) Closes at 2.38, Up/Down 7.69 from Previous Day - The Dwinnex
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
Views of Wall Street’s Leading Experts on XORTX Therapeutics Inc - SETE News
XORTX Recommended by ISS for Shareholder Approval - TipRanks
XORTX Therapeutics Inc (XRTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Independent Proxy Advisory Firm ISS Recommends XORTX - GlobeNewswire
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders - Yahoo Finance
Immersion Corp (NASDAQ: IMMR): An Enticing Stock To Watch - Stocks Register
Comstock Inc (AMEX: LODE) Has Great Upside Potential - Stocks Register
Value of company developing kidney disease treatments doubles in one day - Kursiv Media
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN
XORTX Therapeutics Inc Inc. (XRTX) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Wall Street-Heavily Traded - WDRB
XORTX Therapeutics Gain 87% Following Publication of Research Supporting Treatment Pipeline - MarketWatch
XORTX Therapeutics (XRTX) Stock Up On Major Research Development - Stocks Telegraph
BioCardia Inc (Nasdaq: BCDA) Achieves Significant FDA Clearance for Morph DNA Steerable Introducer, Paving New Pathways in Cardiovascular Interventions - BP Journal
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Nasdaq Surges Over 1%; Best Buy Posts Upbeat Earnings - Benzinga
XORTX’s Research Reinforces Kidney Disease Treatment Strategy - TipRanks
XRTX’s valuation metrics: A comprehensive analysis - US Post News
Dow Jumps Over 100 Points; Nvidia Earnings Top Views - MSN
Earnings and a potential kidney disease breakthrough - RagingBull
XORTX Highlights Pioneering Research Indicating a Role for - GlobeNewswire
XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism - StockTitan
Finanzdaten der Xortx Therapeutics Inc-Aktie (XRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):